Repligen Corp vs. Tarsus Pharmaceuticals, Inc. Common Stock
Repligen Corp (RGEN) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| RGEN | TARS | |
|---|---|---|
| Market Cap | $10.70 billion | $3.61 billion |
| Revenue (TTM) | $785.10 million | $606.33 million |
| Net Income (TTM) | $41.54 million | $-46,476,000 |
RGEN leads on 3 of 3 size & scale factors.
Valuation
| RGEN | TARS | |
|---|---|---|
| P/E Ratio | 259.84 | — |
| Price / Book | 5.07 | 10.40 |
| Price / Sales | 13.63 | 5.95 |
RGEN and TARS split the valuation factors evenly.
Profitability
| RGEN | TARS | |
|---|---|---|
| Net Margin | 5.29% | -7.67% |
| Return on Equity | 1.97% | -13.40% |
RGEN leads on 2 of 2 profitability factors.
Risk & Sentiment
| RGEN | TARS | |
|---|---|---|
| Short Interest | 7.13% | 0.31% |
TARS leads on 1 of 1 risk & sentiment factors.
Dig deeper: RGEN overview, RGEN financials, TARS overview, TARS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.